Artificial active

“Artificial Intelligence Solutions for Understanding and Treating Neurodegenerative Disorders” launched by the International Center for Research on Neurodegenerative Disorders in Prague, Czech Republic

The global conference aims to merge and advance scientific knowledge scattered around the world and apply information technology to identify new treatments for neurodegenerative disorders

INDRC is pioneering the combination of biological sciences and medicine with big data and artificial intelligence approaches to study healthy and diseased human brain function and information processing.

Short-term goal of Build high performance Artificial intelligence/Machine learning platform“Model base”to integrate and explore available conceptual knowledge and experimental data on brain architecture

PRAGUE, August 17, 2022–(BUSINESS WIRE)–INDRC, International Neurodegenerative Disorders Research Center, a private, not-for-profit global research institute established to apply artificial intelligence (AI) and machine learning (ML) solutions to identify and validate therapeutic interventions for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the launch of the INDRC 2022 conference: “Artificial intelligence solutions for the understanding and treatment of neurodegenerative disorders.

The conference will be held on September 7-8, 2022 in Prague, Czech Republic, under the auspices of the Czech Ministry of European Affairs. It is organized within the framework of the Czech Presidency of the Council of the European Union in the autumn of this year, on the occasion of the meeting of the Council of EU Health Ministers.

The Mayor of Prague will host the welcome reception at the Mayor’s Residence of the Municipal Library, an artistic and architectural gem in the art deco style. The conference, co-organized with the Senate of the Parliament of the Czech Republic, will be held in the historic Baroque Kaiserstein Palace in the famous Little Quarter district of Prague.

“INDRC is a pioneering institute, and the first of its kind to combine biological sciences and medicine with big data and artificial intelligence approaches to study human brain function and information processing, with the aim of improve the treatment and prevention of neurodegenerative disorders. the initial goal of the institute is to respond to the major public health demand for a better understanding of the biology behind neurodegeneration and new interventions to treat these devastating diseases,” said Martin Tolar, MD, PhD, Founder and Chairman of the Board of INDRC, and Founder, President and CEO of Alzheon, Inc. “The search for effective treatments remains painfully slow due to the lack of understanding of the complex interrelation between brain structure and brain function, as well as a limited knowledge of the precise pathogenic pathways that alter or destroy neurons and their connections. We identified this critical barrier and founded the INDRC to address these challenges by applying intelligence solutions artificial intelligence and machine learning to study healthy and diseased human brain function and information processing leading to new are therapies. We have brought together the world’s leading experts in neuroscience, clinical research, mathematics, biophysics, biochemistry, bioinformatics, AI and computer science to bridge this gap and create computational models that combine knowledge and expertise to help tackle this major threat to humanity in the near future. coming.”

The INDRC was created to address the challenges faced in identifying and validating novel interventions for neurodegenerative disorders. The INDRC uses a transparent governance model that includes committed international partners from the European Union, North America and around the world, including universities, research institutes, clinical centers and for-profit companies /non-profit. The Institute applies AI and ML to develop new integrated analytical methods using an interdisciplinary approach.

“A major obstacle to the development of new therapies is the lack of understanding of the complex nonlinear networked relationships between the behavioral and clinical characteristics of a given brain disorder with the underlying neurobiological mechanism,” said Ara Khachaturian, PhD, President of the INDRC. Scientific Advisory Board and Executive Vice President of the Alzheimer’s Disease Prevention Campaign. “Currently, neuroscience research communities do not have easy access to data and interpretation tools, which typically reside in advanced, high-performance computer labs and often require technicians, programmers, highly skilled engineers and computer scientists.These disciplines are rarely associated with biomedical research focused on brain disorders, and researchers do not currently possess adequate conceptual models of brain disease, the required research mapping tools, or visualization systems. knowledge to effectively study novel and promising interventions that link the complex origins of brain disorders to clinical symptoms,” Dr. Khachaturian emphasized. “Given the recent challenges in clinical trials to demonstrate effective options to Alzheimer’s disease clinic r and other forms of dementia, the INDRC’s main research priority is to slow the progression and delay the onset of disabling symptoms, so that people with dementia and other forms of dementia brain disorders chronicles can maintain their personal independence.”

The INDRC seeks to establish a new modeling framework to formally examine current theories, as well as clinical and biological knowledge including Alzheimer’s disease and neurodegeneration. This effort will: 1) create an inventory of knowledge on various theories, 2) provide a platform for knowledge management of these theories, 3) establish a common ontology to identify the most crucial aspects that provide links, couplings and /or interfaces between and among the different subsystems within the complete brain architecture, and 4) build a high-performance AI/ML modeling platform – “Modelbase” – to integrate and explore conceptual knowledge and experimental data currently available.

The combination of existing brain biology research and AI/ML computational expertise faces many challenges that the INDRC was designed to overcome. The INDRC aims to mitigate the dispersion of knowledge by developing new methods, models and algorithms to enable the exploration of the complex nonlinear dynamics between biology, environment, disease and public health. The combination of computational and scientific advancements offers tremendous opportunities to advance the understanding of neurodegeneration and potential interventions to help patients with devastating neurodegenerative disorders.

The INDRC concept offers new perspectives through the deployment of AI/ML methods and technologies in all possible layers, such as: 1) AI/ML-enhanced diagnostics, e.g., autonomous cognitive assessment, audio and video analysis, 2) new therapeutic solutions, e.g., ML for protein engineering and new biologically active molecules, 3) AI/ML-enhanced assistance for patient and caregiver care, e.g., devices for support for home care and telemedicine, and 4) prevention and brain health information for health systems, primary care physicians, and individuals, e.g., big data processing of social impacts, professional and lifestyle on individual patients.

The INDRC strives to enable stronger collaboration and communication within the scientific community to reduce unnecessary duplication of effort. The institute aims to facilitate communication within networks, initiatives and research teams, allowing partners to learn from each other and generate synergies.

“INDRC brings together leading experts in the fields of neurodegeneration and artificial intelligence to achieve breakthroughs in the treatment and prevention of Alzheimer’s disease and other neurodegenerative disorders. INDRC has seen tremendous progress over the past year, during which we have accepted several renowned international institutions and established initial research projects, the results of which we will share at our conference,” said INDRC Director Vít Dočkal, PhD. “The INDRC 2022 Conference aims to advance our goal of merging and advancing scientific and technological knowledge dispersed around the world, by bringing together the brightest minds from around the world, who share the vision of the INDRC, to advance the therapies with the greatest impact for patients. Fast-paced information technology in life sciences and neuroscience will accelerate new therapeutic solutions, and we invite the Alzheimer’s disease and AI communities to submit projects, ideas and solutions as we continue our journey.

About the INDRC

The INDRC, International Neurodegenerative Disorders Research Center, is a private, not-for-profit global research institute based in Prague, Czech Republic, which for the first time combines biological sciences and medicine with big data and intelligence approaches artificial to study and treat Alzheimer’s disease. and other neurodegenerative disorders. The goal of the INDRC is to merge and advance the globally dispersed knowledge of brain systems and neurodegeneration through excellence research training fellowship programs, providing outstanding independent research programs , creating a world-class research community and enabling technological and therapeutic innovations with real impact on society. and humanity. The INDRC is interdisciplinary by design, tackling research bottlenecks and developing new analytical approaches to uncover and model the nonlinear dynamics between biology, disease, humans and the environment. The Institute uses a transparent governance model that includes committed international partners from the European Union, North America and around the world, including universities, research institutes, clinical centers and for-profit companies /non-profit. INDRC projects apply artificial intelligence and machine learning to address the challenges of identifying and validating novel therapeutic interventions in Alzheimer’s disease and other neurodegenerative disorders to advance therapies with the greatest impact for patients.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220817005043/en/

contacts

Media:
Christine Rathbun
ViZEN Studios
+1 (401) 578-6165
[email protected]